-+ 0.00%
-+ 0.00%
-+ 0.00%

Axsome Therapeutics (AXSM) Slides As Pipeline Execution Questions Keep Undervalued Narrative Alive

Simply Wall St·11/19/2026 12:14:49
Listen to the news

Axsome Therapeutics (AXSM) has moved sharply lower in recent trading, with the share price at US$134 after declines over the past month and the past 3 months, prompting closer attention from investors.

Axsome Therapeutics has not just slipped in recent weeks; it has given back a chunk of earlier share price gains, with the 30 day share price return down 14% and the 90 day share price return down 35.6%, even though the 3 year total shareholder return is up 122.96% and the 5 year total shareholder return is up 253.28%. This signals fading short term momentum after a very strong longer term run.

Scan Axsome Therapeutics alongside a hand-picked 19 high quality undiscovered gems that have been quietly building long term track records while staying off most investors' radar.

A sharp pullback, a near 50% gap to analyst targets, and a business still reporting losses. Is Axsome Therapeutics now mispriced, or is the market simply pricing those risks in?

Most Popular Narrative: 39% Undervalued

Axsome Therapeutics last closed at $134, while the bearish analyst Narrative on Simply Wall St anchors fair value at $220. This creates a wide gap that hinges on how much of the central nervous system pipeline actually turns into sustained earnings over the next decade.

Management presents an aggregate peak sales opportunity of at least US$18b across the portfolio and a goal of roughly one NDA filing per year into 2031. However, the growing list of late stage programs across smoking cessation, ADHD, binge eating disorder, MDD with excessive sleepiness, fibromyalgia and shift work disorder risks stretching execution and forcing higher trial and launch spending than modeled, which could weigh on net margins even if individual approvals come through.

See why 3 investors see Axsome Therapeutics as 39% undervalued.

Result: Fair Value of $220 (UNDERVALUED)

Still, if Auvelity prescriptions in Alzheimer’s agitation continue to increase and multiple late stage CNS programs secure approvals, the bearish Axsome Therapeutics narrative could quickly look too cautious.

Find out about the key risks to this Axsome Therapeutics narrative.

Next Steps

Sentiment around Axsome Therapeutics is split, and that is exactly when doing your own homework matters most. Move quickly and pressure test the story against the facts by reviewing the 3 key rewards

Looking for more Axsome Therapeutics sized ideas?

If Axsome Therapeutics has your attention, do not stop here. The same toolkit can help you surface other potential opportunities before the crowd catches on.